Does a haplotype of the methylenetetrahydrofolate reductase gene predict poor tumor response in rectal cancer patients receiving preoperative chemoradiation?
Unlike TS VNTR and SNP polymorphisms, MTHFR 677T-1298A haplotype in genomic DNA has the potential to be a predictive marker of tumor response in rectal cancer patients submitted to preoperative chemoradiotherapy.
These results identify the A2BAR as a novel therapeutic target for providing potent protection from renal ischemia.